Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma (TRI Pro)

2 november 2026 bijgewerkt door: Janssen Research & Development, LLC

Phase 2 Randomized, Double-blind, Placebo-controlled Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma

The purpose of this study is to find out whether giving a single dose of tocilizumab before treatment with ramantamig can help prevent or reduce the severity of cytokine release syndrome (CRS) within 28 days from ramantamig, compared to participants who receive placebo. CRS is an acute inflammatory reaction that can occur during treatment and may be associated with flu-like or other systemic symptoms, such as fever and tiredness.

Studie Overzicht

Toestand

Werving

Conditie

Interventie / Behandeling

Studietype

Ingrijpend

Inschrijving (Geschat)

230

Fase

  • Fase 2

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

      • Buenos Aires, Argentinië, C1199ABB
        • Werving
        • Hospital Italiano de Buenos Aires
      • Buenos Aires, Argentinië, C1426ANZ
        • Werving
        • Instituto Alexander Fleming
      • Buenos Aires, Argentinië, C1118
        • Werving
        • Hospital Aleman
      • Córdoba, Argentinië, X5016KEH
        • Werving
        • Hospital Privado Centro Medico de Cordoba
      • Pilar, Argentinië, 1629
        • Werving
        • Hospital Universitario Austral
      • Bedford Park, Australië, 5042
        • Werving
        • Flinders Medical Centre
      • Birtinya, Australië, 4575
        • Werving
        • Sunshine Coast University Hospital
      • Concord, Australië, 2139
        • Werving
        • Concord Repatriation General Hospital
      • Fitzroy, Australië, 3065
        • Werving
        • St Vincents Hospital Melbourne
      • Wollongong, Australië, 2500
        • Werving
        • Wollongong Hospital
      • Argenteuil, Frankrijk, 95107
        • Werving
        • Centre Hospitalier Victor Dupouy
      • Bayonne, Frankrijk, 64100
        • Werving
        • Centre Hospitalier de la Cote Basque
      • La Tronche, Frankrijk, 38700
        • Werving
        • CHU de Grenoble
      • Le Mans, Frankrijk, 72100
        • Werving
        • Centre de Cancerologie de la Sarthe
      • Nantes, Frankrijk, 44000
        • Werving
        • CHU Nantes - Hotel Dieu
      • Quimper, Frankrijk, 29000
        • Werving
        • Centre Hospitalier de Quimper Cornouaille
      • Alexandroupoli, Griekenland, 681 00
        • Werving
        • Uni General Hospital of Alexandroupolis
      • Athens, Griekenland, 11528
        • Werving
        • Alexandra General Hospital of Athens
      • Athens, Griekenland, 115 25
        • Werving
        • 251 Air Force General Hospital
      • Piraeus, Griekenland, 18537
        • Werving
        • Metaxa Cancer Center Hospital Of Piraeus
      • Rio, Griekenland, 265 04
        • Werving
        • General University Hospital of Patras
      • Thessaloniki, Griekenland, 54642
        • Werving
        • Hippokration Hospital
      • Thessaloniki, Griekenland, 546 39
        • Werving
        • Theageneio Cancer Hospital
      • Budapest, Hongarije, 1088
        • Werving
        • Semmelweis Egyetem
      • Budapest, Hongarije, 1097
        • Werving
        • Del Pesti Centrumkorhaz Orszagos Hematologiai es Infektologiai Intezet Szent Laszlo Telephely
      • Budapest, Hongarije, 1122
        • Werving
        • Orszagos Onkologiai Intezet
      • Pécs, Hongarije, 7624
        • Werving
        • Pecsi Tudomanyegyetem Klinikai Kozpont
      • Szeged, Hongarije, 6725
        • Werving
        • Szegedi Tudomanyegyetem Altalanos Orvostudomanyi Kar
      • Ampang, Maleisië, 68000
        • Werving
        • Hospital Ampang
      • George Town, Maleisië, 10450
        • Werving
        • Hospital Pulau Pinang
      • Johor Bharu, Maleisië, 80100
        • Werving
        • Hospital Sultanah Aminah
      • Kota Kinabalu, Maleisië, 88586
        • Werving
        • Hospital Queen Elizabeth
      • Kuching, Maleisië, 93586
        • Werving
        • Sarawak General Hospital
      • Braga, Portugal, 4710 243
        • Werving
        • Uls Braga - Hosp. Braga
      • Lisbon, Portugal, 1099 023
        • Werving
        • Ipo Lisboa
      • Lisbon, Portugal, 1998 018
        • Werving
        • Hosp. Cuf Descobertas
      • Porto, Portugal, 4200 319
        • Werving
        • Uls Sao Joao - Hosp. Sao Joao
      • Porto, Portugal, 4050 342
        • Werving
        • Uls Santo Antonio - Hosp. Santo Antonio
      • Vila Nova de Gaia, Portugal, 4434 502
        • Werving
        • Uls Gaia Espinho
      • Barcelona, Spanje, 08041
        • Werving
        • Hosp. de La Santa Creu I Sant Pau
      • León, Spanje, 24071
        • Werving
        • Hosp. de Leon
      • Madrid, Spanje, 28046
        • Werving
        • Hosp. Univ. La Paz
      • Madrid, Spanje, 28055
        • Werving
        • Hosp. Blua Sanitas Valdebebas
      • Málaga, Spanje, 29010
        • Werving
        • Hosp Regional Univ de Malaga
      • Pamplona, Spanje, 31008
        • Werving
        • Hosp. de Navarra
      • Valencia, Spanje, 46017
        • Werving
        • Hosp. Univ. Dr. Peset
    • Arizona
      • Goodyear, Arizona, Verenigde Staten, 85338
        • Werving
        • City of Hope Phoenix
    • California
      • Beverly Hills, California, Verenigde Staten, 90211
        • Werving
        • Beverly Hills Cancer Center (BHCC)
      • Irvine, California, Verenigde Staten, 92618
        • Werving
        • City of Hope Orange County Lennar Foundation Cancer Center
      • Palo Alto, California, Verenigde Staten, 94304
        • Werving
        • Stanford University Medical Center
    • Colorado
      • Denver, Colorado, Verenigde Staten, 80218
        • Werving
        • Colorado Blood Cancer Institute
    • Missouri
      • St Louis, Missouri, Verenigde Staten, 63110
        • Werving
        • Washington University School Of Medicine
    • Ohio
      • Columbus, Ohio, Verenigde Staten, 43214
        • Werving
        • Ohio Health Research Institute
    • Tennessee
      • Nashville, Tennessee, Verenigde Staten, 37203
        • Werving
        • Sarah Cannon Research Institute
    • Utah
      • Salt Lake City, Utah, Verenigde Staten, 84112
        • Werving
        • University of Utah Huntsman Cancer Institute
      • Falun, Zweden, 791 82
        • Werving
        • Falu Lasarett Medicinkliniken Falun
      • Gothenburg, Zweden, 413 45
        • Werving
        • Sahlgrenska Universitetssjukhuset
      • Lund, Zweden, 221 85
        • Werving
        • Skanes universitetssjukhus
      • Stockholm, Zweden, 141 86
        • Werving
        • Karolinska University Hospital Huddinge
      • Uppsala, Zweden, 752 37
        • Werving
        • Akademiska Sjukhuset

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion criteria:

  • Documented diagnosis of multiple myeloma (MM) as defined by the criteria: a. MM diagnosis according to the international myeloma working group (IMWG) diagnostic criteria; b. Measurable disease at screening as assessed by local laboratory as defined in the protocol
  • Received at least 1 prior lines of antimyeloma therapy
  • Relapsed or refractory disease as defined: a. Relapsed disease is defined as an initial response to prior treatment, followed by confirmed progressive disease (PD) by the IMWG response criteria greater than (>) 60 days after cessation of treatment.; b. Refractory disease is defined as failure to achieve a response or confirmed PD by the IMWG response criteria during previous treatment or less than or equal to (<=) 60 days after cessation of treatment
  • Have an eastern cooperative oncology group (ECOG) performance status (PS) score of 0 to 2 at screening and immediately before the start of study treatment administration. Participants with ECOG PS 2 or 3 are eligible for the study if the ECOG PS score is related to stable physical limitations (example, wheelchair-bound due to prior spinal cord injury) and not related to MM or associated therapy
  • Have clinical laboratory values meeting the criteria specified in the protocol

Exclusion criteria:

  • Concurrent use of any other anticancer treatment (including non-palliative radiotherapy) or investigational agent
  • Major surgery, (for example, requiring general anesthesia) within 2 weeks before first dose, or will not have fully recovered from surgery, or has surgery planned during the time the participant is expected to participate in the study
  • Suspected or known allergies, hypersensitivity, or intolerance to ramantamig and tocilizumab or their excipients
  • Presence of any of the following: a. Any ongoing myelodysplastic syndrome or B-cell malignancy (other than MM); b. Any history of malignancy, other than MM, that is considered at high risk of recurrence requiring systemic therapy; c. Any active malignancy other than MM
  • Known active or prior central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of MM. If either is suspected, negative whole brain magnetic resonance imaging (MRI) and lumbar cytology are required

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Preventie
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Dubbele

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Arm A: Tocilizumab + Ramantamig

Participants will receive tocilizumab along with ramantamig. Ramantamig will be administered for a total treatment of finite duration, or until progressive disease (PD) or intolerable toxicity (whichever is earlier).

Ramantamig will be administered as subcutaneous (SC) injection.

Andere namen:
  • JNJ-79635322

Tocilizumab will be administered as intravenous (IV) injection.

Placebo-vergelijker: Arm B: Placebo + Ramantamig

Participants will receive placebo (saline) along with ramantamig. Ramantamig will be administered for a total treatment of finite duration, or until PD or intolerable toxicity (whichever is earlier).

Ramantamig will be administered as subcutaneous (SC) injection.

Andere namen:
  • JNJ-79635322

Placebo (saline) will be administered as IV injection.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Percentage of Participants Alive and Free of Treatment-Emergent American Society for Transplantation and Cellular Therapy (ASTCT) Grade Greater Than or Equal to (>=) 2 Cytokine Release Syndrome (CRS)
Tijdsspanne: By the end of Day 28 from first ramantamig dose

Percentage of participants alive and free of treatment-emergent ASTCT Grade >=2 CRS without the use of intervening treatment for CRS of any grade by the end of day 28 from first ramantamig dose will be reported.

By the end of Day 28 from first ramantamig dose

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Percentage of Participants with Treatment-Emergent CRS of any ASTCT Grade, Grade >=2, and Grade >=3 by the End of Day 28 from First Ramantamig Dose
Tijdsspanne: By the end of Day 28 from first ramantamig dose

Percentage of participants with treatment-emergent CRS of any ASTCT Grade, Grade >=2, and Grade >=3 by the end of day 28 from first ramantamig dose, respectively, will be reported.

By the end of Day 28 from first ramantamig dose
Percentage of Participants with Treatment-Emergent CRS of any ASTCT Grade, Grade >=2, and Grade >=3 During Ramantamig Treatment
Tijdsspanne: Up to 38 months

Percentage of participants with treatment-emergent CRS of any ASTCT Grade, Grade >=2, and Grade >=3 during ramantamig treatment will be reported.

Up to 38 months
Percentage of Participants with Re-occurrence of CRS with ASTCT Grade >=2 After the Initial Occurrence of Treatment-Emergent Grade >=2 CRS Event
Tijdsspanne: Up to 38 months

Percentage of participants with re-occurrence of CRS with ASTCT Grade >=2 after the initial occurrence of treatment-emergent Grade >=2 CRS event will be reported.

Up to 38 months
Percentage of Participants with Re-occurrence of CRS for All Grades
Tijdsspanne: Up to 38 months

Percentage of participants with re-occurrence of CRS for all Grades will be reported.

Up to 38 months
Overall Response
Tijdsspanne: Up to 38 months

Overall response is defined as the percentage of participants who achieve partial response (PR) or better prior to progressive disease (PD) or subsequent antimyeloma therapy, in accordance with the international myeloma working group (IMWG) criteria.

Up to 38 months
Complete Response (CR) or Better
Tijdsspanne: Up to 38 months

CR or better rate is defined as the percentage of participants achieving CR or stringent complete response (sCR) prior to PD or subsequent antimyeloma therapy, in accordance with the IMWG criteria.

Up to 38 months
Very Good Partial Response (VGPR) or Better
Tijdsspanne: Up to Month 38

VGPR or better rate is defined as the percentage of participants achieving VGPR, CR or sCR prior to PD or subsequent antimyeloma therapy, in accordance with the IMWG criteria.

Up to Month 38
Duration of Response (DoR)
Tijdsspanne: Up to 38 months

DoR is defined as the time interval between the date of initial documentation of a response (PR or better) to the date of first documented evidence of PD according to the IMWG response criteria or death due to any cause, whichever occurs first.

Up to 38 months
Time to Response (TTR)
Tijdsspanne: Up to 38 months

TTR is defined as the time from the date of randomization to the date of first documentation of a confirmed response (PR or better) for participants who have PR or better as their best response.

Up to 38 months
Progression-Free Survival (PFS)
Tijdsspanne: Up to Month 38

PFS is defined as the duration from the date of randomization to either PD or death, whichever comes first. Disease progression will be determined according to the IMWG response criteria.

Up to Month 38
Time to Subsequent Antimyeloma Therapy
Tijdsspanne: Up to Month 38

Time to subsequent antimyeloma therapy is defined as the time from randomization to the start of subsequent antimyeloma treatment. Death due to progressive disease without the start of any subsequent antimyeloma therapy will be considered as an event.

Up to Month 38
Percentage of Participants With Treatment-Emergent Adverse Event (TEAE) by Severity
Tijdsspanne: Up to 38 months

An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product. Any new or worsening AE occurring at or after the initial administration of study treatment through the day of last dose plus 30 days or prior to the start of subsequent antimyeloma therapy, whichever is earlier, or any follow-up AE (linked to an existing TEAE) with onset date and time beyond 30 days after the last dose of study treatment but prior to the start of subsequent therapy, or any AE that is considered treatment-related regardless of the start date of the event, is considered to be treatment-emergent. TEAEs will be graded according to the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 6.0. Severity scale ranges from Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening, Grade 5= death related to adverse event.

Up to 38 months
Percentage of Participants with Abnormalities in Laboratory Parameters
Tijdsspanne: Up to 38 months

Percentage of participants with abnormalities in laboratory parameters (serum chemistry and hematology) will be reported.

Up to 38 months
Percentage of Participants with Incidence of Adverse Events of Clinical Interests
Tijdsspanne: Up to 38 Months

Percentage of participants with incidence of adverse events of clinical interests such as cytopenia will be reported.

Up to 38 Months

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Onderzoekers

  • Studie directeur: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

30 juni 2026

Primaire voltooiing (Geschat)

31 december 2027

Studie voltooiing (Geschat)

30 juli 2030

Studieregistratiedata

Eerst ingediend

11 mei 2026

Eerst ingediend dat voldeed aan de QC-criteria

11 mei 2026

Eerst geplaatst (Werkelijk)

15 mei 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

3 november 2026

Laatste update ingediend die voldeed aan QC-criteria

2 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • 79635322MMY2002
  • 2025-524793-42 (EudraCT-nummer)
  • 2025 (Subsidie/contract van de Amerikaanse NIH)

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

product vervaardigd in en geëxporteerd uit de V.S.

Ja

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .